Delving into the Latest Updates on Ainuovirine/Lamivudine/Tenofovir Disoproxil Fumarate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ACC007/Lamivudine/Tenofovir Disoproxil Fumarate, 复方ACC007, 艾诺韦林/拉米夫定/富马酸替诺福韦二吡呋酯

+ [4]

Target

RT

Action

inhibitors

Mechanism

RT inhibitors(Viral reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

Jiangsu Aidea Pharmaceutical Co., Ltd.

Active Organization

Jiangsu Aidea Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization

Kainos Medicine, Inc.

Jiangsu Aidea Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

China (30 Dec 2022),

HIV Infections

RegulationSpecial Review Project (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC23H34N5O14P

InChIKeyVCMJCVGFSROFHV-WZGZYPNHSA-N

CAS Registry202138-50-9

View All Structures (3)

AbstractThis was a single‐dose, randomized, open‐label, 2‐period crossover study to evaluate the bioequivalence of the ACC008 (test formulation [T]) versus coadministered ainuovirine (ANV) 150 mg, lamivudine (3TC) 300 mg, and tenofovir disoproxil fumarate 300 mg (reference formulation [R]) in the fasted state among the Chinese healthy adults. Eligible subjects were randomized into 2 cohorts to received treatment in 1 of 2 sequences (T → R, R → T). PK samples were collected from 1 hour before dosing to 144 hours after dosing in each period. The concentrations of ANV, 3TC, and tenofovir in plasma were determined by liquid chromatography–tandem mass spectrometry. Phoenix WinNonlin software was used for pharmacokinetic parameter calculation and bioequivalence evaluation. All the 90% confidence intervals of maximum concentration, area under the concentration–time curve from time zero to the last detectable time, and area under the concentration–time curve from time zero to infinity fell within the bioequivalence range. The safety was comparable between the 2 treatments, with no Grade III/VI or serious adverse events. ACC008 was bioequivalent to administration of its individual components, including ANV 150 mg, 3TC 300 mg, and tenofovir disoproxil fumarate 300 mg with favorable safety profile.

01 May 1980·Canadian journal of surgery. Journal canadien de chirurgieQ4 · MEDICINE

Relief of postoperative pain by ibuprofen: a report of two studies.

Q4 · MEDICINE

Article

Author: Iles, J D

The value of ibuprofen (Motrin) as an analgesic was assessed in two consecutive studies in 425 patients with postherniorrhaphy pain. In the first study, 400 mg ibuprofen proved superior to placebo and as effective as one tablet of a compound containing 375 mg of acetylsalicylic acid, 30 mg caffeine and 8 mg codeine (ACC-8). In the second study, the analgesic effectiveness of 400 mg of ibuprofen was intermediate between that of two tablets of ACC-8 and one tablet of ACC-30 (a compound containing 375 mg ASA, 30 mg caffeine and 30 mg codeine). The side effects of all drugs were negligible. Ibuprofen should be a suitable alternative analgesic in postoperative pain of this type.

Frontiers in Pharmacology

Current drugs for HIV-1: from challenges to potential in HIV/AIDS

Review

Author: Zong, Yanjun ; Chen, Zhe-Sheng ; Wang, Dongfeng ; Chen, Junbing ; Peng, Fujun ; Liu, Zhijun ; Peng, Yuan

The human immunodeficiency virus (HIV) persists in latently infected CD4+T cells and integrates with the host genome until cell death. Acquired immunodeficiency syndrome (AIDS) is associated with HIV-1. Possibly, treating HIV/AIDS is an essential but challenging clinical goal. This review provides a detailed account of the types and mechanisms of monotherapy and combination therapy against HIV-1 and describes nanoparticle and hydrogel delivery systems. In particular, the recently developed capsid inhibitor (Lenacapavir) and the Ainuovirine/tenofovir disoproxil fumarate/lamivudine combination (ACC008) are described. It is interestingly to note that the lack of the multipass transmembrane proteins serine incorporator 3 (SERINC3) and the multipass transmembrane proteins serine incorporator 5 (SERINC5) may be one of the reasons for the enhanced infectivity of HIV-1. This discovery of SERINC3 and SERINC5 provides new ideas for HIV-1 medication development. Therefore, we believe that in treating AIDS, antiviral medications should be rationally selected for pre-exposure and post-exposure prophylaxis to avoid the emergence of drug resistance. Attention should be paid to the research and development of new drugs to predict HIV mutations as accurately as possible and to develop immune antibodies to provide multiple guarantees for the cure of AIDS.

100 Deals associated with Ainuovirine/Lamivudine/Tenofovir Disoproxil Fumarate

Login to view more data